Lars H. Lund, Stefan James, Adam D. DeVore, Kevin J. Anstrom, Marat Fudim, Keith D. Aaronson, Ulf Dahlström, Patrice Desvigne-Nickens, Jerome L. Fleg, Song Yang, Michael Fu, Camilla Hage, Claes Held, Patric Karlström, Magnus Nygren, Eric D. Peterson, Tymon Pol, Shelly Sapp, Johan Sundström, Ollie Östlund, Jonas Oldgren, Bertram Pitt
{"title":"保留射血分数的心力衰竭患者螺内酯起始注册随机介入试验（SPIRRIT-HFpEF）：原理与设计","authors":"Lars H. Lund, Stefan James, Adam D. DeVore, Kevin J. Anstrom, Marat Fudim, Keith D. Aaronson, Ulf Dahlström, Patrice Desvigne-Nickens, Jerome L. Fleg, Song Yang, Michael Fu, Camilla Hage, Claes Held, Patric Karlström, Magnus Nygren, Eric D. Peterson, Tymon Pol, Shelly Sapp, Johan Sundström, Ollie Östlund, Jonas Oldgren, Bertram Pitt","doi":"10.1002/ejhf.3453","DOIUrl":null,"url":null,"abstract":"Benefits of mineralocorticoid receptor antagonists (MRAs) in heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF) have not been established. Conventional randomized controlled trials are complex and expensive. The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF) is a unique pragmatic registry-based randomized controlled trial.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"2 1","pages":""},"PeriodicalIF":16.9000,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design\",\"authors\":\"Lars H. Lund, Stefan James, Adam D. DeVore, Kevin J. Anstrom, Marat Fudim, Keith D. Aaronson, Ulf Dahlström, Patrice Desvigne-Nickens, Jerome L. Fleg, Song Yang, Michael Fu, Camilla Hage, Claes Held, Patric Karlström, Magnus Nygren, Eric D. Peterson, Tymon Pol, Shelly Sapp, Johan Sundström, Ollie Östlund, Jonas Oldgren, Bertram Pitt\",\"doi\":\"10.1002/ejhf.3453\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Benefits of mineralocorticoid receptor antagonists (MRAs) in heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF) have not been established. Conventional randomized controlled trials are complex and expensive. The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF) is a unique pragmatic registry-based randomized controlled trial.\",\"PeriodicalId\":164,\"journal\":{\"name\":\"European Journal of Heart Failure\",\"volume\":\"2 1\",\"pages\":\"\"},\"PeriodicalIF\":16.9000,\"publicationDate\":\"2024-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Heart Failure\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ejhf.3453\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ejhf.3453","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF): Rationale and design
Benefits of mineralocorticoid receptor antagonists (MRAs) in heart failure with preserved and mildly reduced ejection fraction (HFpEF/HFmrEF) have not been established. Conventional randomized controlled trials are complex and expensive. The Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction (SPIRRIT-HFpEF) is a unique pragmatic registry-based randomized controlled trial.
期刊介绍：
European Journal of Heart Failure is an international journal dedicated to advancing knowledge in the field of heart failure management. The journal publishes reviews and editorials aimed at improving understanding, prevention, investigation, and treatment of heart failure. It covers various disciplines such as molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, clinical sciences, social sciences, and population sciences. The journal welcomes submissions of manuscripts on basic, clinical, and population sciences, as well as original contributions on nursing, care of the elderly, primary care, health economics, and other related specialist fields. It is published monthly and has a readership that includes cardiologists, emergency room physicians, intensivists, internists, general physicians, cardiac nurses, diabetologists, epidemiologists, basic scientists focusing on cardiovascular research, and those working in rehabilitation. The journal is abstracted and indexed in various databases such as Academic Search, Embase, MEDLINE/PubMed, and Science Citation Index.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
